Exelixis’s Cabometyx advances mCRPC treatment with big trial validation questions
Patients treated with Cabometyx and Tecentriq had a 35% lower risk of disease progression or death than those treated with a second novel hormone therapy.
Patients treated with Cabometyx and Tecentriq had a 35% lower risk of disease progression or death than those treated with a second novel hormone therapy.